IP Verse

Dosage Form Containing Oxycodone And Naloxone - EP2962686

The patent EP2962686 was granted to Euro Celtique on Apr 10, 2019. The application was originally filed on Feb 28, 2006 under application number EP15180143A. The patent is currently recorded with a legal status of "Revoked".

EP2962686

EURO CELTIQUE
Application Number
EP15180143A
Filing Date
Feb 28, 2006
Status
Revoked
Oct 22, 2021
Grant Date
Apr 10, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARISTO PHARMAJan 9, 2020GILLE HRABAL PARTNERSCHAFTSGESELLSCHAFT MBB PATENTANWALTEADMISSIBLE
ETHYPHARMJan 9, 2020REGIMBEAUADMISSIBLE
TEVA PHARMACEUTICALSJan 9, 2020D YOUNGADMISSIBLE
KRKASep 24, 2019HOFFMANN EITLEADMISSIBLE
STADA ARZNEIMITTELAug 8, 2019KERNEBECKADMISSIBLE
DEVELCO PHARMA SCHWEIZApr 11, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
HEXAL SANDOZApr 11, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE4325465
DESCRIPTIONEP0352361
DESCRIPTIONUS3773955
DESCRIPTIONUS3966940
DESCRIPTIONUS4457933
DESCRIPTIONUS4582835
DESCRIPTIONUS6258042
DESCRIPTIONWO03073937
DESCRIPTIONWO03084520
OPPOSITIONEP0352361
OPPOSITIONWO02092060
OPPOSITIONWO03084504
OPPOSITIONWO03084520
OPPOSITIONWO2006089973
OPPOSITIONWO9825613
SEARCHWO02092060
SEARCHWO03084504

Non-Patent Literature (NPL) Citations (30) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Supportive MaBnahmen in der Onkologie", Die Schmerzbehandlung von Tumorpatienten, THIEME, (1994), vol. 3-
DESCRIPTION- ZECH, D.; GROND, S.; LYNCH, J.; HERTEL, D.; LEHMANN, K., "Validation of World Health Organisation Guidelines for Cancer Pain Relief: a 10-year prospective study", PAIN, (1995), vol. 63, pages 65 - 76-
OPPOSITION- Anonymous, "Mobile PDR", Physicians Desk Reference, (20050000), pages 1 - 10, XP055664566-
OPPOSITION- Anonymous, "Mobile PDR", Physician's Desk Reference, (20050000), pages 1 - 11, XP055664566-
OPPOSITION- Anonymous, "Product information: oxycodone hydrochloride and naloxone hydrochloride anhydrous", Orbis ra-0106, (2016120585), pages 1 - 32, XP055664563-
OPPOSITION- Anonymous, "Targinact 5mg/2.5mg, 10mg/5, 20mg/10 mg and 40 mg/20 mg prolonged release tablets", EMC, (20130510), pages 1 - 16, XP055664576-
OPPOSITION- Fiche technique-
OPPOSITION- M. HOPP et al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - Results of a clinical study", German Pain Congress, (20050000), vol. 19, page 103, XP055583675-
OPPOSITION- M. HOPP et al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - Results of a clinical study", German Pain Congress, Bremen, (20050000), vol. 32, no. 10, XP055583652-
OPPOSITION- M. HOPP et al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Mundipharma research, Bremen, (20051000), XP055641999-
OPPOSITION- M. HOPP et al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - Results of a clinical study", Poster 11.2 presented at the German Pain Congress, Bremen, (20050000), vol. 32, no. 10, XP055583652-
OPPOSITION- M. HOPP et al., "Influence of an addition of naloxone to prolonged release (pr) oxycodone on the analgesic efficacy -results of a clinical study", Schmerz, (20050000), vol. 19, page 103, XP055583675-
OPPOSITION- M. HOPP et al., "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Schmerz 2005, (20051000), vol. 19, no. 1, page 103, XP055642010-
OPPOSITION- M. HOPP et al., "The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Mundipharma research, Bremen, (20051000), XP055583669-
OPPOSITION- M. HOPP et al., "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation - Results of a clinical study", German Pain Congress, (20050000), XP055583669-
OPPOSITION- Michael Hopp et al., "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", Poster 11.2 presented at the German Pain Congress, (20050000), XP055583669-
OPPOSITION- page from Barnes and Noble homepage showing the publication date of El;-
OPPOSITION- "Physician's Desk Reference", Barnes and Noble, (20050130), pages 2818 - 2822, XP055583650-
OPPOSITION- "Product Information on Targin@", Targin, (20100512), pages 1 - 32, XP055583654-
OPPOSITION- "Product Information on Targin@", TARGIN, (20100512), pages 1 - 32, XP055583654-
OPPOSITION- "Product information TARGIN modified release tablets", TARGIN and OXYCONTIN, pages 1 - 32, XP055627499-
OPPOSITION- Purdue Frederick, Physicians' Desk Reference 2005, (20050130), pages 2818 - 2822, XP055627467-
OPPOSITION- Thomson, "PDR - for all of your drug information needs", Mobile PDR, (20050130), pages 1 - 10, XP055641991-
OPPOSITION- ZENZ et al., Lehrbuch der Schmerztherapie, Stuttgart, (20010000), pages 255 - 280 , 462-463, XP055583646-
OPPOSITION- Zenz/Jurna, "Lehrbuch der Schmerztherapie", Stuttgart, (20010000), pages 255 - 280 , 462-463, XP055583646-
OPPOSITION- LIU et al., Journal of Pain and Symptom Management, (20020100), vol. 23, no. 1, XP055252523
OPPOSITION- N. D. HAWKES et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine", Aliment. Pharmacol. Ther., (20010000), vol. 15, doi:doi:10.1046/j.1365-2036.2001.00970.x, pages 625 - 630, XP055408359
OPPOSITION- N.D. HAWKES et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine", Aliment Pharmacol Ther, (20010000), vol. 15, no. 5, pages 625 - 630, XP055408359
OPPOSITION- B. BAIERL, "Intelligente Schmerztherapie - Hohe Analgesie bei gleichzeitiger Regulation der Darmtätigkeit", Notfall & Hausarztmedizin, (20050000), vol. 32, no. 10, page 466, XP055583687
OPPOSITION- B. BAIERL, "Intelligente Schmerztherapie - Hohe Analgesie bei gleichzeitiger Regulation der Darmtätigkeit", Notfall & Hausarztmedizin, (20060000), vol. 32, no. 10, page 466, XP055583687

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents